Bacterial infections in hemodialysis patients: Pathogenesis and prevention  by Jaber, Bertrand L.
Kidney International, Vol. 67 (2005), pp. 2508–2519
NEPHROLOGY FORUM
Bacterial infections in hemodialysis patients: Pathogenesis
and prevention
Principal discussant: BERTRAND L. JABER
Department of Medicine, Tufts University School of Medicine; and Division of Nephrology, Department of Medicine,
Caritas St. Elizabeth’s Medical Center, Boston, Massachusetts
CASE PRESENTATION
A 62-year-old African American man with end-stage
renal disease secondary to hypertension who had been
treated with hemodialysis for almost 5 years had multi-
ple vascular access problems. After multiple thrombec-
tomies of right and left arm arterio-venous grafts (AVGs),
as well as an episode of life-threatening bleeding from
the left arm AVG, he underwent insertion of a LifeSite®
catheter in the left internal jugular vein 4 years ago. Four
months later, he was hospitalized for an episode of chills
and rigors, and was found to have methicillin-resistant
Staphylococcus aureus (MRSA) bacteremia, which was
treated with intravenous vancomycin and oral rifampin.
A trans-esophageal echocardiogram revealed no valvu-
lar vegetation. Because he was a nasal carrier of MRSA,
he was given a 2-week course of mupirocin ointment to
his nares for eradication of MRSA colonization.
Extensive discussions ensued with the patient about
the future of his vascular access and the likelihood of
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eradicating the infection with medical therapy alone.
Given his history of multiple thrombosed AVGs, and that
the implanted catheter might have been his last option for
satisfactory dialysis access, the decision was made not to
remove the catheter and for him to receive an 8-week
course of dual antibiotic therapy. The patient then did
well until 13 months later, when erosion of the skin over
the arterial port of the LifeSite® catheter required surgi-
cal relocation of the port and skin closure.
Seventeen months later, he presented with fever and
abdominal pain one day following a dialysis session.
Blood cultures from a peripheral vein and from the
dialysis catheter grew coagulase-negative staphylococcus
species. An abdominal CT scan revealed pneumatosis
and air tracking in the superior mesenteric and splenic
veins consistent with ischemic bowel disease. Broad-
spectrum antibiotics were initiated and he was given
intravenous fluids prior to undergoing an emergent ex-
ploratory surgery. Laparotomy revealed a gangrenous
small bowel from the ligament of Treitz to the ileo-cecal
valve. Intraoperative Doppler studies revealed no pulse
in the arcade of the mesentery of the small intestine. Be-
cause of these findings and the overall poor prognosis, no
intestinal resection was attempted, and the abdominal
surgical wound was closed. As expected, the patient con-
tinued to deteriorate clinically and died due to this dev-
astating complication and overwhelming staphylococcal
sepsis. No autopsy was performed.
DISCUSSION
DR. BERTRAND L. JABER (Department of Medicine,
Tufts University School of Medicine; and Vice Chair-
man for Clinical Affairs, Division of Nephrology, Depart-
ment of Medicine, Caritas St. Elizabeth’s Medical Center,
Boston, Massachusetts): Bacterial infections represent a
common and important health problem for patients with
end-stage renal disease (ESRD) who undergo mainte-
nance hemodialysis (HD), and this patient illustrates the
challenges inherent to this problem. Considerable gains
have been made in deciphering the pathogenesis of bac-
terial infections in this high-risk population. These gains
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notwithstanding, the therapeutic goal of preventing bac-
terial infections in HD patients remains unfulfilled. This
Forum reviews the magnitude of the problem in the HD
patient population, our progress in understanding the
pathogenesis of bacterial infections, the use of novel di-
agnostic tools, and prospects for preventing such occur-
rences, while outlining areas of uncertainty.
The clinical problem
Infection is an important cause of morbidity and mor-
tality among patients with ESRD. According to the
United States Renal Data System (USRDS) registry,
infection is the second leading cause of death in pa-
tients with ESRD (the first is cardiovascular disease), and
septicemia accounts for more than 75% of these infec-
tious deaths [1]. Indeed, among ESRD patients undergo-
ing dialysis, the total death rate is 176/1000 patient-years,
and septicemia and pulmonary infections combined ac-
count for close to 26/1000 patient-years [1]. Annual death
rates due to pneumonia and sepsis are markedly higher in
dialysis patients compared with the general population;
in the 65- to 74-year-old category, the magnitude of dif-
ference is on the order of 10- and 100-fold, respectively
(Fig. 1) [2, 3]. Whereas the presence of diabetes mellitus
confers an additional risk for sepsis-related deaths, this
comorbid condition appears to exert little influence on
pneumonia-related deaths [2, 3].
Bacterial infections are a major cause of hospitaliza-
tion. In a recent study on the epidemiology of septicemia
in HD patients, hospital admission rates for septicemia
during the first year of HD rose by 51% over the 8-year
period from 1991 to 1999 [4]. Hospitalization for sep-
ticemia also was associated with an increased risk of my-
ocardial infarction, congestive heart failure, stroke, and
peripheral vascular disease at 6 months and 5 years after
the original hospitalization [4]. These data suggest that
septicemia has become more common in dialysis patients
in the U.S. and is associated with an increased risk of car-
diovascular events and death. Evidence is emerging that
HD patients also have a higher incidence of infective en-
docarditis [5–7]. In one study, the proportion of patients
with infective endocarditis who were undergoing HD in-
creased from 7% to more than 20% over a 7-year period
[5], and this observation was paralleled by a significant in-
crease of Staphylococcus aureus-associated endocarditis
from 10% to 68% [5]. In the U.S., the incidence of infec-
tive endocarditis in the dialysis population has been es-
timated at 483 episodes/100,000 patient-years compared
with only 7 episodes in the general population [6]. In this
study, HD therapy was a strong risk factor for infective
endocarditis, which was associated with a 1.5-fold higher
risk of death [6].
In a longitudinal cohort study of incident ESRD pa-
tients, older age and diabetes were independent risk fac-
tors for septicemia in all patients [8]. Among HD patients,
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Fig. 1. Annual death rates due to sepsis (A) and pulmonary infections
(B) among dialysis patients (black line) compared with the general pop-
ulation (gray line). The data are stratified by age and are shown on a
logarithmic (A) or normal (B) scale. Reproduced with permission from
[2, 3].
low serum albumin level, temporary vascular access, and
dialyzer reuse also were associated with increased risk
[8], and septicemia carried a markedly increased risk of
death. These data suggest that improving nutrition and
avoiding temporary vascular access might decrease the
incidence of septicemia, and that dialyzer reuse practices
might contribute to this risk. In a recent study reporting
on a staged program to stop dialyzer reprocessing, conver-
sion to a single-use dialyzer practice was associated with
improved survival [9]. This trend lagged by at least 60
days following abandonment of the dialyzer reuse prac-
tice and was ascribed to a cumulative decline in exposure
to trace industrial products or repeated inflammatory and
infectious insults, which only become clinically manifest
over time [9].
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Fig. 2. Pathogenesis of bacteremia in hemodialysis patients. Gray boxes contain common pathogenic factors, white boxes therapeutic strategies.
In the HEMO study, the incidence of infection-related
deaths was not reduced by higher dose of dialysis or
by high-flux dialyzers, and most infection-related hos-
pitalizations were not attributed to vascular access [10].
However, the frequency of infection-related hospitaliza-
tions attributed to vascular access was disproportionately
higher among patients with central venous catheters com-
pared with those who had grafts or fistulas [10].
Pathogenesis
In the past two decades, major gains have been realized
in our understanding of the pathogenesis of bacterial in-
fections in HD patients. I will emphasize the interaction of
three pivotal factors: host immunity, bacterial virulence,
and the dialysis procedure per se (Fig. 2). The following
section reviews the various components of this “access of
evil,” with special emphasis on the pathogenesis of bac-
teremia and bacterial pneumonia.
Impaired host immunity. Uremia is associated with al-
terations in primary host defense mechanisms, which in-
crease the risk of bacterial infections. Indeed, neutrophils
exhibit impaired chemotaxis, oxidative metabolism,
phagocytic activity, degranulation, and intracellular
killing, as well as dysregulated programmed cell death or
apoptosis [11–14]. A number of factors have been incrim-
inated in neutrophil dysfunction, including malnutrition,
trace element deficiencies, iron overload, impaired glu-
cose metabolism, hyperparathyroidism, dialysis per se,
and uremic retention solutes [12, 15–18].
Abundant in vitro and clinical studies have linked iron
overload to an increased risk of bacterial infections in HD
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Fig. 3. Kaplan-Meier survival curves for bacterial infections (bac-
teremia and pneumonia) stratified by iron storage indices prior to initi-
ation of intravenous iron therapy. Functional iron deficiency is defined
as ferritin = 100 to 800 ng/mL and transferrin saturation (TSAT) <20%;
iron deficiency, ferritin <100 ng/mL and TSAT <20%; and iron replete
state, ferritin = 100 to 800 ng/mL and TSAT >20%. Reproduced with
permission from [23].
patients [17, 19–21], including modest iron storage levels
(ferritin level of 100–800 ng/mL and transferrin satura-
tion of 10% to 50%) (Fig. 3) [22, 23]. Iron overload mod-
ulates this risk by affecting host defense mechanisms and
bacterial virulence. Indeed, iron overload has been as-
sociated with reduced phagocytic function and oxidative
burst, as well as impaired bacterial killing [17, 20, 21].
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Iron dextran, at pharmacologically relevant concentra-
tions, attenuates in vitro the function of polymorphonu-
clear cells harvested from HD patients with normal iron
indices [24]. Also, it is possible that the increased avail-
ability of iron can stimulate bacterial growth and increase
virulence properties [25]. Consequently, the increased
use of parenteral iron might be an important contribu-
tory factor to the occurrence of bacterial infections.
In recent years, many uremic retention solutes that can
adversely affect neutrophil function have been identified,
including parathyroid hormone, p-cresol, polyamines,
aminoguanidine products, and a series of granulocyte
inhibitory proteins, angiogenin and complement factor D
[12, 18]. In addition, neutrophil-membrane interactions,
mainly with cuprophan membranes, result in transient
leukopenia, increased expression of adhesion molecules,
degranulation and release of proteolytic enzymes, and re-
lease of reactive oxygen species [26]. These interactions
might result in cellular “exhaustion” and decreased re-
sponsiveness to subsequent stimuli, such as bacteremia.
Other striking abnormalities occur in cell-mediated
immunity and primarily involve T-lymphocytes. These
include lymphocytopenia, impaired delayed skin reactiv-
ity, and decreased in vitro lymphocyte proliferation [26,
27]. Alterations in B-lymphocyte function affect humoral
immunity and result in decreased immunoglobulin levels
and a depressed antibody response to antigens. Dysreg-
ulated cytokine synthesis [28] and impaired macrophage
Fc receptor function [29] further impair immune function
in uremic patients. In one study, impaired macrophage
Fc receptor function was associated with a higher risk of
bacterial infection [29]. Finally, impaired ex vivo cytokine
production by mononuclear cells in response to IgG, an
Fc-mediated response, was associated with an increased
risk of hospitalization for bacterial infections in HD pa-
tients [30].
Additional susceptibility and risk factors that are spe-
cific for pulmonary infections in HD patients include ob-
structive and central sleep apnea, impaired inspiratory
muscle strength, uremic pneumonitis/pleuritis, the hyper-
hydration syndrome (due to fluid gain during the interdi-
alytic interval), pulmonary metastatic calcification (from
an increased calcium × phosphate product), and intra-
dialytic hypoxemia (due to complement activation and
transient leukopenia) [2, 31].
Bacterial virulence and adherence properties. Bacte-
ria can acquire virulence properties when specific con-
ditions are met. In the normal host, under conditions of
low density, bacteria are cleared by primary host-defense
mechanisms. However, under conditions of high bacterial
density, bacteria can produce extracellular polysaccha-
rides referred to as “quorum sensors” [32, 33]. These
molecules are secreted by the bacteria and freely dif-
fuse within the bacterial community, where they interact
with transcriptional activators such as LasR and RhlR.
This interaction increases expression of virulence genes,
thereby facilitating bacterial survival by increased pro-
duction of proteases, superoxide dismutase, and catalase,
which enable the organisms to evade neutrophil killing
and the bactericidal or bacteriostatic effects of antimicro-
bial agents. Bacteria also form a matrix of these extracel-
lular polysaccharides, which is called biofilm or “slime.”
This slime renders them less susceptible to antimicrobial
agents, as the matrix constitutes a barrier between the an-
timicrobial agent and the bacterial cell wall. In the pres-
ence of foreign surfaces such as central venous catheters,
biofilm formation is more likely to develop and can po-
tentiate the pathogenicity of the skin bacterial flora (for
example, coagulase-negative staphylococci).
The adherence properties of bacteria are also impor-
tant determinants of catheter-related infection [34]. For
example, S. aureus adheres to host proteins that are com-
monly present on catheters, such as fibronectin, whereas
coagulase-negative staphylococci directly adhere to poly-
mer surfaces.
The hemodialysis procedure. During the normal
course of HD, patients are exposed to several infec-
tious risks. Potential sources of infection include the skin
(through repeated disruption of the skin barrier and in-
tegrity due to the nature of the vascular access type), the
dialysis water treatment system, and dialyzer reuse.
Central venous catheters used for HD include non-
tunneled, tunneled, and totally implantable devices, such
as the one described in the case presentation. The risk
of bacteremia by device type, site of insertion, and du-
ration of use varies widely. In one study of non-tunneled
catheters, the incidence of bacteremia was 5% after three
weeks of placement in the internal jugular vein, and 11%
after one week in the femoral vein [35]. Four pathogenic
pathways have been incriminated in the development of
catheter-related bloodstream infections, and include, in
order of descending frequency: (1) colonization of the
cutaneous catheter tract and tip with skin flora; (2) intra-
luminal colonization due to contamination of the catheter
hub; (3) hematogenous seeding to the catheter from an-
other focus of infection; and (4) very rarely, intralumi-
nal contamination of the catheter with solvent/infusate.
In addition to intrinsic bacterial virulence factors, an-
other important determinant of catheter-related infec-
tion is the type of the device material [34]. For exam-
ple, catheters made of polyvinyl chloride or polyethylene
are less resistant to the adherence of bacteria compared
with catheters made of polytetrafluoroethylene (PTFE),
silicone elastomer, or polyurethane [36]. Finally, surface
irregularities and thrombogenicity of the catheter mate-
rial are also likely to influence microbial adherence and
therefore increase the risk of catheter colonization and
catheter-related infection.
Bacteremia also can result from contamination
of dialysis fluids or equipment, inadequate dialyzer
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reprocessing procedures, or inadequate treatment of mu-
nicipal water for use in dialysis [37, 38]. Contaminated
medication vials also are a potential source of bacteremia
[39].
Novel diagnostic approaches for catheter-related
infections
The confirmation of peripheral bacteremia is
paramount in the diagnosis of catheter-related in-
fections. Unfortunately, for practical purposes often only
one set of blood cultures is collected from the catheter
lumen itself. Although blood culture testing is relatively
inexpensive and easy to process, 24 to 48 hours often
elapse before a preliminary report is provided to the
clinician. In addition, if a catheter removed on suspicion
of causing infection proves not to be infected, the patient
is exposed unnecessarily to the risks associated with
reinsertion. Consequently, rapid diagnostic approaches
that help confirm a suspected catheter-related infection
in HD patients and that implement the proper use
of antibiotics are needed. Several novel but rather
cumbersome diagnostic approaches include the use of an
endoluminal brush, catheter hub culture, and electron
microscopy [40, 41]. One rapid diagnostic technique,
however, merits discussion. The acridine-orange leuko-
cyte cytospin test (AOLC) is rapid (30 min), inexpensive,
and requires only 100 lL of catheter blood and the use
of ultraviolet microscopy [42]. In a study of diagnostic
approaches of catheter-related bloodstream infections in
adult surgical patients, the AOLC provided a diagnostic
sensitivity and specificity of 96% and 92%, respectively,
compared with traditional quantitative peripheral blood
cultures [43]. Although this simple and rapid diagnostic
method compares favorably with traditional blood
culture techniques and might help stratify patients
who require catheter removal and early antimicrobial
therapy, further studies are needed on the sensitivity and
specificity of this assay in the dialysis population.
Preventive strategies
Strategies for the prevention of bacterial infections in
HD patients, mainly bacteremia and pneumonia, should
focus on the dialysis procedure with a primary goal of
preventing catheter-related infections and on boosting
host immunity.
Prevention of catheter-related infections. In recent
years, numerous studies have attempted to address this
problem, as the prevalence of catheter use in the ESRD
population is on the rise. I will summarize the most
promising approaches.
The LifeSite® HD Access System, a totally implantable
catheter, in one study outperformed a tunneled catheter
in terms of bacteremia and technical device survival [44].
A subsequent study, however, reported a high infection
rate, which was ascribed either to the learning curve as-
sociated with its use or to its liberal use in a population of
chronically ill patients [45]. These data strongly suggest
that no catheter device can eliminate the infectious risk
that is inherent in the dialysis population.
In the past decade, the topical use of antibiotics
and ointments at catheter sites has gained popularity.
A randomized controlled trial of prophylactic topical
administration of povidone-iodine ointment compared
with sterile gauze dressings alone on the incidence of
subclavian catheter-related infections in HD patients
demonstrated a marked reduction in bacteremia rates
(2% versus 17%) [46]. A subsequent trial comparing
mupirocin ointment with povidone-iodine for preventing
non-tunneled catheter-related infections demonstrated
similar findings [47]. In this study, the use of mupirocin
resulted in fewer episodes of S. aureus-related bacteremia
(1 versus 9 episodes/1000 patient days) and a longer dura-
tion of catheter use (median of 37 versus 20 days). More
recently, a meta-analysis of 10 studies (totaling 2445 pa-
tients) on the use of mupirocin prophylaxis to prevent S.
aureus infection in dialysis patients reported a 78% risk
reduction in bacteremia among HD patients; this percent-
age compared with only a 66% risk reduction in peritoni-
tis among patients on peritoneal dialysis [48]. Whereas
mupirocin prophylaxis substantially reduces the rate of S.
aureus infection in the dialysis population, optimal reg-
imens that minimize the emergence of mupirocin resis-
tance need to be explored.
A multicenter, double-blind, placebo-controlled, ran-
domized controlled trial compared the prophylactic use
of topical Polysporin® Triple formulation with a placebo
ointment on the incidence of tunneled catheter-related
infections in HD patients [49]. This triple agent contains
bacitracin, gramicidin, and polymyxin B, and has strong
topical activity against staphylococci and Gram-negative
bacteria. The study demonstrated a 60% to 65% risk re-
duction in bacteremia over a 6-month period [49]. An un-
expected 78% risk reduction in death also was observed.
This study is relevant as it was contemporaneous with the
well-established catheter care guidelines of the National
Kidney Foundation [50], and the study sample was repre-
sentative of the HD population in the U.S. However, de-
spite the low cost of this prophylactic triple agent and its
lower susceptibility to microbial resistance, an increased
risk of fungal infections, particularly in the immunocom-
promised patient, was a concern raised by these investiga-
tors. These studies on the use of topical agents suffer from
our inability to compare more than two agents. Clearly, a
study should be designed that establishes the superiority
of Polysporin® Triple, mupirocin, or povidone-iodine for
tunneled catheters.
In the new millennium, an effort has been made to
preserve dialysis catheters while combating antimicro-
bial resistance. Catheter lock solutions have emerged as
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Table 1. Antibiotic lock solutions for dialysis catheters
Antimicrobial agent Final drug concentration Anticoagulant agent Final drug concentration Reference
Taurolidine 1.35% Sodium citrate 4% [53, 54]
Gentamicin 40 mg/mL Tri-sodium citrate 3.13% [51]
Vancomycin 2.5 mg/mL Heparin 2500 units/mL [56]
Gentamicin 1 mg/mL Heparin 2500 units/mL [56]
Vancomycin + gentamicin 2.5 mg/mL + 1 mg/mL Heparin 2500 units/mL [56]
Cefazolin 5 mg/mL Heparin 2500 units/mL [56]
Cefazolin + gentamicin 5 mg/mL + 1 mg/mL Heparin 2500 units/mL [56]
novel approaches for the primary and secondary pre-
vention of dialysis catheter-related infection (Table 1).
A randomized controlled trial for the prevention of
tunneled catheter-related infections using a gentamicin-
citrate catheter lock solution demonstrated a marked
reduction in infections compared with the use of hep-
arin [51]. In addition, the incidence of catheter malfunc-
tion did not differ significantly between the two groups.
However, predialysis gentamicin levels were significantly
higher in patients randomized to the gentamicin-citrate
catheter lock solution. The achievement of these systemic
levels is the result of instilling a relatively high concentra-
tion of gentamicin in the catheter (Table 1) and therefore
warrants a note of caution.
Taurolidine, a derivative of the amino acid taurine, is an
antimicrobial agent that inhibits and kills a broad range
of micro-organisms [52]. Its combination with citrate as
an anticoagulant and its use as a catheter lock solution
for preventing infections has recently been examined [53,
54]. In two small studies, the taurolidine-citrate catheter
lock solution reduced the incidence of non-tunneled and
tunneled catheter-related infections. However, in one
study [53], unassisted catheter patency was lower among
patients who received the taurolidine-citrate catheter
lock than among control patients (32% versus 76%).
Trisodium citrate, at low concentration (2.2% to 15.0%),
has antimicrobial activity against staphylococcal strains;
however, higher concentrations (30%) are required for
killing Gram-negative bacteria [55]. These data suggest
that the optimal concentration of citrate required for an-
timicrobial effect and anticoagulation remains unknown
and warrants further investigation. An additive or syn-
ergistic antimicrobial effect between citrate and more
traditional antimicrobial agents also requires further in-
quiry. In one study, the adjunctive use of an antibiotic
lock (Table 1) in conjunction with systemic antibiotic ther-
apy eradicated catheter-associated bacteremia while sal-
vaging the catheter in close to 50% of cases [56]. This
approach might be advantageous over routine catheter
removal but warrants confirmation by further investiga-
tion.
Additional experimental agents that have not yet been
tested in humans are worthy of mention. In an in vitro
model of biofilm formation on polyurethane surfaces,
linezolid (2 mg/mL) and eperezolid (4 mg/mL) achieved
eradication of Staphylococcus epidermidis biofilms more
rapidly than did vancomycin (10 mg/mL) and genta-
micin (10 mg/mL) [57]. Other catheter lock agents that
have shown promise include recombinant tissue plas-
minogen activator (rTPA) [58], tetrasodium EDTA [59],
and RNAIII-inhibiting peptide (RIP), a molecule that in-
terferes with “quorum-sensing” mechanisms, thereby re-
ducing adherence of S. aureus to catheter polymers [60].
Finally, catheters and cuffs have been impregnated
with antimicrobial or antiseptic agents in an effort
to reduce catheter-related infections [34]. These in-
clude platinum/silver- and silver-impregnated cuffs, and
chlorhexidine-silver-, sulfadiazine-, and minocycline-
rifampin-impregnated catheters. Among these rela-
tively new and expensive devices, minocycline-rifampin–
impregnated catheters are the only catheters that have
demonstrated efficacy in reducing catheter-related blood-
stream infections in HD patients [61].
Boosting host immunity. Strategies for boosting im-
munity in HD patients include vaccination against com-
mon infectious agents such as staphylococcus species,
influenza virus, and Pneumococcus pneumoniae, and the
experimental use of recombinant human granulocyte
colony-stimulating factor (rhG-CSF) to modulate im-
mune responses. Uremic patients, especially those under-
going dialysis, have decreased responses to vaccination.
This defect has been ascribed to their inability to achieve
and maintain protective antibody levels secondary to
impaired macrophage function, T- and B-lymphocyte
activation and proliferation, and immunoglobulin
production [62–65].
Whereas the administration of the influenza vaccine
has been associated with improved outcomes in dialysis
patients, less than 50% of the population is vaccinated in
the U.S. on a yearly basis [66]. These vaccination rates fall
very short of the goal of 90% for the general population,
which is targeted for the year 2010 [67].
In a large randomized controlled trial of HD pa-
tients, the administration of a capsular polysaccharide-
protein conjugate anti-staphylococcal vaccine reduced
the incidence of bacteremia secondary to S. aureus [65].
Unfortunately, this vaccine was associated with an un-
acceptable side effect profile and its cumulative effi-
cacy was short-lived. Protective antibody titers reached a
peak by 30 weeks and were followed by a rapid decline.
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Nevertheless, these encouraging results await further
testing. Finally, administration of the pneumococcal vac-
cine to dialysis patients has been associated with a subop-
timal antibody response by 2 years, warranting a repeat
dose [62]. In summary, dialysis patients benefit from in-
fluenza vaccination, which is safe, efficacious, and cost
effective. Dialysis providers therefore should immunize
this high-risk group each year. Similarly, pneumococcal
vaccination should be recommended to all dialysis pa-
tients, and revaccination is warranted every 3 to 5 years.
The rationale for using immune-modulating strategies
such as rhG-CSF in HD patients is the reversal of neu-
trophil dysfunction. Indeed, in addition to the mobi-
lization of neutrophils from the bone marrow, rhG-CSF
directly enhances chemotaxis, phagocytosis, and respira-
tory burst, while decreasing apoptosis and thereby re-
versing much of the neutrophil dysfunction of uremia [14,
68]. When assessed as an adjuvant therapy to systemic an-
tibiotics for the treatment of severe diabetic foot infec-
tions, rhG-CSF treatment improved neutrophil function,
accelerated resolution of the infection, and shortened the
hospital length of stay [69]. This drug, as well as other
immune-modulating strategies, awaits further investiga-
tion in the dialysis population.
Areas of uncertainty
As dialysis providers in the U.S. try to prevent and com-
bat bacterial infections effectively, two emerging prob-
lems need to be acknowledged and rapidly contained:
bacterial resistance and suboptimal vascular access care.
Emerging bacterial resistance. In the most recent
survey of patient care practices and dialysis-associated
diseases in the U.S. during the period of 1995 to 2001,
the percentage of patients who received dialysis through
central catheters increased from 13% to 25% [70].
This trend is worrisome, as infections and antibiotic
use—the “breeding ground” for emergence of bacte-
rial resistance—are higher among patients who have
dialysis catheters. Indeed, over the same period, the
percentage of centers reporting infections or coloniza-
tion with vancomycin-resistant enterococcus (VRE) and
methicillin-resistant S. aureus (MRSA) increased from
12% to 31%, and 40% to 72%, respectively (Fig. 4)
[70]. Colonization of dialysis patients with VRE is highly
correlated with the outpatient use of vancomycin [71].
Of more concern is a recent report on the epidemiol-
ogy of the 19 patients reported to date who were in-
fected with vancomycin-intermediate S. aureus (VISA)
[72]. This analysis suggests that whereas dialysis status
was not a risk factor for the emergence of this resistant
micro-organism, the use of vancomycin in the previous 1
to 6 months was highly correlated with these infections
[72]. All these data point to the importance of the judi-
cious use of antibiotics in the dialysis patient population,
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Fig. 4. Dialysis facilities in the United States reporting colonization or
infection with vancomycin-resistant enterococcus (VRE, gray line) or
methicillin-resistant Staphylococcus aureus (MRSA, black line). The
data are provided by the national surveillance of dialysis-associated
diseases, 1995–2001, United States. Reproduced with permission from
[70].
and the avoidance of vancomycin whenever possible, in
an effort to minimize the emergence of bacterial resis-
tance.
Improving vascular access care. Results from the 2002
ESRD Networks’ Clinical Performance Measures (CPM)
reveals that the prevalence of arteriovenous fistulas in
the U.S. has not yet reached the goal of 40% put forward
by the K/DOQI guidelines [73]. Of more concern is the
prevalence of catheter use, which has remained above
the target of 10%, reaching close to 25% in 2001 [70, 73].
Data from Europe suggest that for patients in whom arte-
riovenous fistulas are difficult to achieve, long-term use of
tunneled catheters such as the Tesio catheter (a twin-line
single-lumen central venous catheter) is an acceptable
alternative [74]. Notwithstanding, in the U.S., a national
vascular access improvement initiative known as “Fistula
First” is aimed at solving the problem by increasing the
use of fistulas for Medicare beneficiaries with ESRD, with
the hope of reaching a goal of 40% [75]. This rather am-
bitious initiative will require close multidisciplinary col-
laboration, but more important, earlier referrals to the
nephrologist and to the vascular surgeon for the timely
creation of arteriovenous fistulas [76].
QUESTIONS AND ANSWERS
DR. NICOLAOS E. MADIAS (Chairman, Department of
Medicine, Caritas St. Elizabeth’s Medical Center, Boston,
Massachusetts): What is the impact of the chronic use of
antibiotic ointment at the exit site of the dialysis catheter
on the risk of bacterial resistance and yeast colonization?
DR. JABER: This is a real long-term concern. For in-
stance, in the study by Lok and colleagues [49], the au-
thors used an ointment that had three active ingredients
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to ensure both synergism of action and minimization of
bacterial resistance. There is a clear need for long-term
studies aimed at examining whether bacterial virulence
of the skin flora develops, and whether there is a colo-
nization shift from bacteria to yeast which, in turn, would
predispose the patient to more serious catheter-related
infections.
DR. MADIAS: Do you see a role for rTPA as a fibri-
nolytic agent for the prevention of both catheter throm-
bosis and catheter-related infections?
DR. JABER: Nephrologists traditionally have used
rTPA to maintain catheter patency. This practice has tra-
ditionally been driven by a catheter malfunction. How-
ever, this fibrinolytic agent also might prevent bacterial
biofilm formation in the catheter lumen by stripping the
intraluminal fibrin coat, which is one of the first steps in
the adherence of micro-organisms to polymers. This hy-
pothesis, which was originally proposed by Dr. Bernard
Canaud [58], warrants formal testing in a randomized
controlled trial of thrice-weekly rTPA versus heparin as
a catheter lock solution.
DR. ANTO´NIO SARMENTO: (Nephrology Service, Hos-
pital de San Anto´nio, Porto, Portugal): You briefly re-
viewed the relationship between iron overload and the
risk of bacterial infection. Do you have any recommen-
dations on how to prescribe intravenous iron in terms of
frequency and dose?
DR. JABER: As you know, iron metabolism is tightly
regulated; humans normally absorb 1 mg/day of elemen-
tal iron by the gut. A patient undergoing maintenance
dialysis who receives a typical intravenous infusion of
iron receives on the order of 25 to 100 mg, which is 25- to
100-fold higher than the normal daily intestinal absorp-
tion of iron. More important, this dose of iron received
intravenously undergoes no first-pass liver clearance and
immediately reaches the systemic circulation. Nephrolo-
gists have to be mindful about doses of intravenous iron
in the context of iron metabolism. There is a need for
a clinical trial to examine whether lower doses of intra-
venous iron, on the order of 10 mg or less per dose, would
correct iron deficiency anemia effectively while minimiz-
ing iron toxicity. For the time being, using the K/DOQI
guidelines, which recommend 25 to 100 mg doses, I would
basically err on the side of administering the lower dose.
However, in the face of an acute episode of bacteremia,
intravenous iron therapy should be temporarily discon-
tinued until the bacteremia has resolved because of the
potential effect of iron on bacterial growth.
DR. ANı´BAL FERREIRA: (Nephrology Service, Hospital
Curry Cabral, Lisboa, Portugal): As you know, vitamin
D is an important immunomodulator. Are you aware of
any data examining the impact of vitamin D therapy on
the risk of infections in dialysis patients?
DR. JABER: Vitamin D is used as hormone replacement
therapy for vitamin D deficiency, to prevent osteomala-
cia, and as pharmacotherapy to suppress parathyroid hor-
mone secretion. The immunomodulatory effects of vita-
min D at pharmacologic doses remain poorly understood
in my opinion. Whereas the recent work by Thadhani’s
group sheds some light on the differential impact of two
vitamin D formulations on all-cause mortality, the study
did not address infectious outcomes [77]. I am not aware
of any other study that has examined the impact of vita-
min D therapy on infectious morbidity.
DR. GERALD APPEL (Professor of Clinical Medicine,
Columbia University College of Physicians and Surgeons,
New York, New York): Many dialysis patients have an-
ticardiolipin antibodies, and these have been related to
a thrombotic tendency. Is there any relation between in-
fection and the presence of anticardiolipin antibodies in
HD patients with either fistulas or grafts?
DR. JABER: I am not aware of any published work link-
ing these two entities. But clearly a hypercoagulable state
is likely to influence vascular access malfunction and, in
the case of a catheter, might predispose to adherence of
bacteria to host proteins in the catheter lumen and con-
sequently to colonization and bacteremia. It is possible
that the presence of anticardiolipin antibodies in HD pa-
tients is indeed the result of a smoldering infection, which
would solicit an immune response; however, this is purely
speculative.
DR. PEDRO PONCE (Chief of Nephrology, Hospital
Garcia de Orta, Almada, Portugal): Is there any ratio-
nale for waiting a certain period of time before inserting
a tunneled catheter in a patient with bacteremia? We usu-
ally wait at least 48 hours after the removal of an infected
catheter before reinserting one. Is there any proof that
we can colonize the new catheter?
DR. JABER: This question has a multifaceted answer,
as it merges science and art. Whenever you’re dealing
with a catheter-related bacteremia, specifically, with S.
aureus, which is very difficult to eradicate, it is not rec-
ommended that a tunneled catheter be reinserted dur-
ing the course of bacteremia. Once you have established
that at least two surveillance blood cultures are negative
following the removal of the catheter, you can proceed
with the insertion of a tunneled catheter at a different
site; this will minimize the likelihood of introducing the
catheter along a previously infected track. The issue of
catheter removal versus conservative therapy with antibi-
otics is a delicate issue often debated by infectious disease
consultants and nephrologists. For coagulase-negative
staphylococcus species, you might be able to treat with
antibiotics alone and not sacrifice the catheter unless
there is persistent bacteremia or recurrence after discon-
tinuation of the antimicrobial therapy. Unfortunately, no
evidence supports such a recommendation. As I men-
tioned earlier, Krishnasami and colleagues demonstrated
that the adjunctive use of an antibiotic lock in conjunction
with systemic antibiotic therapy might be advantageous
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over routine catheter removal [56]. However, this war-
rants further investigation.
DR. MADIAS: Can you reflect on the potential impact
of bacterial infections on future cardiovascular morbidity
and mortality?
DR. JABER: This area is gaining momentum in the U.S.
Recent work by Foley and colleagues established a strong
link between infectious morbidity and cardiovascular
morbidity and mortality. Indeed, dialysis patients who
are hospitalized for septicemia have a four- to tenfold
higher risk of subsequent development of myocardial in-
farction, heart failure, stroke, or cardiovascular death [4].
This is not surprising, as an episode of septicemia is of-
ten associated with hypotension, which in turn can lead
to hypoperfusion of the coronary arterial bed and, con-
sequently, a non–Q-wave myocardial infarction. Such a
scenario in my opinion is not uncommon in clinical prac-
tice and is exemplified in today’s case presentation, in
which staphylococcal bacteremia led to septic shock and
ischemic bowel disease, and resulted in the death of the
patient. In summary, a hemodynamic insult from sepsis
renders the patient more vulnerable to a secondary car-
diovascular insult, thereby increasing the risk of cardio-
vascular morbidity and mortality. This emerging concept
is in keeping with the new paradigm of inflammation, in-
fection, and cardiovascular mortality.
DR. ANABELA RODRIGUES (Nephrology Service, Hos-
pital de S. Anto´nio, Porto, Portugal): If you allow me, this is
more of a comment than a question. With such a tremen-
dous impact on morbidity and mortality from vascular
access–related bacteremia in HD patients, isn’t it time to
demystify peritonitis in PD patients and to offer PD as
an excellent alternative in an aging population, a group
that presumably has much more vascular access–related
complications, as opposed to waiting for access exhaus-
tion?
DR. JABER: I fully agree with you. In the U.S., the chal-
lenge we’re facing is that the utilization of PD is declining,
while the popularity of HD continues to increase. Some of
the concerns include the limited training of nephrologists
in management of PD, the lack of physician incentive in
recommending this therapy to our patients, lack of patient
interest in self-care dialysis, and the fact that renal trans-
plantation is competing with PD, especially pre-emptive
renal transplantation.
DR. RODRIGUEZ: The topic is controversial, but cer-
tainly PD offers several advantages, even with fewer bac-
teremic episodes and even pulmonary infections. Clearly
it is an option, and a first option in the elderly dialysis
population.
DR. JABER: In the U.S., the incident PD patient pop-
ulation is, on average, 10 years younger than its HD
counterpart. The provision of PD to the elderly dialysis
population is more challenging, as it often requires the
active participation of a caregiver, such as a spouse, and
these caregivers can become overburdened by this com-
mitment. Nevertheless, I strongly agree with you that PD
should be offered to the aging population because of poor
vascular access options, especially among those who have
some residual renal function and who are not candidates
for renal transplantation.
DR. JOA˜O CARLOS FERNANDES (Nephrology Service,
Centro Hospitalar de Vila Nova de Gaia, Portugal): Would
you comment on the incidence of endocarditis among pa-
tients with prosthetic cardiac valves, and how their pres-
ence can or should influence the choice of vascular access
and the treatment plan for infectious complications?
DR. JABER: The presence of prosthetic valves poses
a greater risk of endocarditis and metastatic infections
among dialysis patients with venous catheter and arte-
riovenous grafts. The decision should be individualized,
and in a patient contemplating dialysis initiation who has
limited vascular access options, PD might be a wise ap-
proach. Although PD patients are still at risk of develop-
ing peritonitis, as you know, this infectious complication
is almost never associated with systemic bacteremia, and
PD would offer a lower risk of endocarditis for the pa-
tient with a prosthetic valve. In the case of bacteremia in a
patient with a prosthetic valve, transechocardiography to
document the presence of valvular vegetation and a pro-
longed (6- to 8-week) course of dual antibiotic therapy
with weekly surveillance blood cultures is likely the best
practice. However, in the case of S. aureus bacteremia or
fungemia, it is extremely likely that valvular replacement
would be required if medical therapy fails.
DR. MADIAS: What might be the impact of dialyzer
reuse on infectious morbidity and mortality?
DR. JABER: As you know, in the U.S. the practice of
dialyzer reuse is purely economic in nature, as it has al-
lowed the reuse of high-flux dialyzers, which are more
expensive. In recent years, however, high-flux dialyzers
have become more affordable in the U.S., and this has
prompted dialysis facilities to stop their reuse program.
Lowrie and colleagues recently demonstrated that con-
version to a single-use dialyzer practice was associated
with improved survival [9]. This was ascribed in part to a
decline in exposure to repeated infectious insults.
DR. PONCE: Since the early ‘90s, we have tried to
avoid the outpatient use of vancomycin as the initial em-
piric treatment of fever in HD patients, although this
approach is more practical and less expensive than a hos-
pital admission. What is the risk of avoiding the initial
use of vancomycin, especially in the old and frail pa-
tient who is febrile, and using instead a first-generation
cephalosporin? My concern is that since it takes 48 to
72 hours to obtain the result of a blood culture and an-
tibiotic sensitivities, using the wrong empiric antibiotic
regimen might be harmful. By avoiding vancomycin, I
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am concerned that lives are being lost in the name of
public health.
DR. JABER: I fully agree with your concern that we
should consider using the best drug. Although bacteremia
in dialysis patients is often due to coagulase-negative
staphylococcus species, these bacteria, as well as MRSA,
are always resistant to methicillin, and this renders the
medical decision regarding the proper antibiotic more
challenging. A similar example is the initial choice of
antibiotics for peritonitis. A discrepancy exists between
the guidelines put forward by the International Society
of PD [78] and the microbial flora of these infections,
which typically consist of coagulase-negative staphylo-
coccus species [79]. On the other hand, we need to ac-
knowledge that the uncontrolled use of vancomycin in
the ambulatory setting is the strongest predictor of bac-
terial resistance, including the emergence of VRE and
VISA.
DR. FERREIRA: Cardiac valvular calcifications are
more prevalent than prosthetic valves, reaching 40% in
some groups. Do you think that we should adopt a dif-
ferent approach to these patients? Specifically, should we
be performing more echocardiograms and providing en-
docarditis prophylaxis for patients with cardiac valvular
calcifications?
DR. JABER: I don’t know. However, a recent study by
Eicher and colleagues demonstrated that mitral annular
calcification appears to be an underestimated predispos-
ing factor for a particularly severe type of bacterial en-
docarditis [80]. One can only speculate as to the value
of endocarditis prophylaxis prior to dental work in the
setting of valvular calcifications among dialysis patients.
DR. PATRICIA MARTINS (Nephrology Service, Hospital
de S. Joa˜o, Porto, Portugal): What is your personal choice
for a skin antiseptic agent?
DR. JABER: I would recommend the use of chlorhexi-
dine for skin antisepsis. However, in the case of a catheter,
the topical use of an antibiotic/antiseptic ointment war-
rants further investigation by contacting the catheter
manufacturer to ensure that the chemical ingredients of
the ointment are compatible with the polymer material
of the catheter. There have been cases of catheter ero-
sion due to incompatibility with the antiseptic/antibiotic
ointment. Therefore, it is critical that one obtain this in-
formation before instituting such a policy in a dialysis
facility.
DR. MADIAS: You commented on the role of immune-
modulating strategies for the uremic patient, strategies
aimed at boosting host defense mechanisms. Specifically,
you mentioned vaccinations and G-CSF. What about the
potential use of cytokine inhibitors?
DR. JABER: Although the use of cytokine inhibitors
appears to be an elegant approach for combating the
inflammatory milieu of uremia, it remains unproven. A
recent pharmacokinetic study of anakinra (a synthetic
interleukin-1 receptor antagonist) in subjects with differ-
ent levels of renal function demonstrated that little re-
moval occurs by dialysis, which would require a dose or
schedule adjustment [81]. Unfortunately, in the rheuma-
tologic literature, this and other cytokine inhibitors have
been associated with an increased risk of infection, and
this risk might render the dialysis patient population in-
creasingly vulnerable. Although many investigators are
intrigued by the use of cytokine inhibitors in dialysis pa-
tients, until we have a better understanding of how to
assess immune surveillance while a patient is taking such
a drug, the potential long-term benefit of cytokine in-
hibitors remains speculative.
DR. PONCE: I would like to return to the issue of
prevention. You reviewed several preventive strategies,
including some extremely expensive, some still exper-
imental, and others more practical. Obviously, your
own preference is to use topical ointments, such as a
polysporin. I am concerned, however, that we are forced
into using more expensive prevention strategies because
it is an easier approach than the implementation of easier
measures, such as standard hygiene precautions. In your
opinion, what should we do in terms of prevention?
DR. JABER: I would concentrate on hand hygiene and
aseptic techniques for accessing the vascular access. In
case of an AV fistula or graft, I would emphasize the
need to scrub and rinse the arm prior to cannulation.
With venous catheter use, I would use proper catheter
site dressing regimens. In terms of antibiotic or antiseptic
ointments, I would use the agent that is most biocompati-
ble with the catheter material. Finally, I would discourage
the patient from taking a shower as to avoid moisture at
the catheter site.
DR. MADIAS: Of the various preventive and therapeu-
tic possibilities, which ones might be the most appealing
and promising for future studies?
DR. JABER: I have summarized three preventive stud-
ies against catheter-related infections, which examined
either the topical use of betadine, mupirocin, or Triple
Polysporin ointment. Unfortunately, these studies do
not allow us to draw conclusions about the best oint-
ment. A randomized controlled trial comparing these
three agents is warranted. With regard to antibiotic-
impregnated catheters, they are unlikely to become rou-
tinely used because of their exorbitant price. Finally, 40%
of dialysis patients have diabetes mellitus, which further
compromises host immunity, so I believe that this high-
risk group should be the target of these preventive studies.
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